Uri Herzberg

Dr. Herzberg is joining Brickell Bio with over two decades of industry experience, focusing on translational and preclinical development of small molecules, antibodies, and cell-based therapies. While training at NIH, he elucidated the mechanisms by which cannabinoids modulate neuropathic pain and the role of inflammation and Nerve Growth Factor (NGF) in painful neuropathy. He established the preclinical capabilities at Acorda, lead TRPv1 in-vivo program at Neurogen, and developed localized drug delivery concepts at Johnson and Johnson. At Celgene, he led the translational and preclinical development of several cell-based products, with successful regulatory milestones and mechanistic understanding for several indications. At Celularity he headed the Regulatory Affairs Department and at Cabaletta Bio he was instrumental in opening an IND for MuSK Myasthenia Gravis

Dr. Herzberg earned his BSc and DVM from Washington State University, a Ph.D. in veterinary biology and neuroimmunology from the University of Minnesota, and an MBA in Pharmaceutical Development from Fairleigh Dickinson University. He is a board member of the National Bone Marrow Donor Program.